诺和诺德长效生长激素III期研究成功;默沙东新型抗菌药物锐可博在华上市

Ofweek维科网
13 May

诺和诺德长效生长激素III期研究成功。5月12日,诺和诺德公布了REAL8篮子试验的数据,结果显示:每周给药一次的Sogroya在改善小于胎龄儿、努南综合征、特发性矮小症的青春期前儿童的年生长速率方面,与每日给药一次的生长激素Norditropin相当。此外,在患有努南综合征的儿童中,Sogroya较每日一次的生长激素具有优越性,同时在小于胎龄儿的儿童中,Sogroya较每日低剂量的生长激素也具有...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10